GeneThera to Advance RNA Interference Work Through Collaboration Agreement.

WHEAT RIDGE, Colo. -- GeneThera, Inc. (OTCBB:GTHA) is pleased to update its shareholders with this release announcing the continuation of work done earlier by the Company on RNA Interference (RNAi) in its Colorado laboratory.

RNA interference is used to regulate gene expression in the cells of humans. Hundreds of genes in our genome encode small RNA molecules called microRNAs. They contain pieces of the code of other genes. Such a microRNA molecule can form a double-stranded structure and activate the RNA interference machinery to block protein synthesis. The expression of that particular gene is silenced. Genetic regulation by microRNAs plays an important role in the development of the organism and the control of cellular functions.

RNAi has already become an important research tool in biology and biomedicine. In the future, it is hoped that it will be used in many disciplines including clinical medicine and agriculture. Several recent publications show successful gene silencing in human cells and experimental animals. For instance, a gene causing high blood cholesterol levels was recently shown to be silenced by treating animals with silencing RNA. Plans are underway to develop silencing RNA as a treatment for virus infections, cardiovascular diseases, cancer, endocrine disorders and several other conditions.

"With the collaboration agreement in place with IZSLER, GeneThera can now advance our previous research work to the next stage with our access to experimentally infected cattle," said Dr. Tony Milici, CEO of GeneThera. "We had received some promising results on some specific cell lines using RNAi but were unable to continue the research until infected cattle were available".

"With a Nobel prize being issued this year to two highly respected scientists for their discovery and research on RNAi, we feel that it is of great importance for the regulation of gene expression and it may lead to advances in vaccine programs for both animals and humans. Large pharmaceutical companies are beginning to understand the importance of RNAi as evidenced by Merck's recent purchase of Sirna Therapeutics and GeneThera hopes to further its use of RNAi as a discovery tool in our TSE studies as well."

About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA[TM], a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA[TM] is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, which are diseases affecting cattle worldwide.

Stay up to date with Market NewsWire at www.mn1.com.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.